Close

Pfizer (PFE) Presents Encouraging New Data for INLYTA Combo Phase 1b in Adv. RCC

Go back to Pfizer (PFE) Presents Encouraging New Data for INLYTA Combo Phase 1b in Adv. RCC

Pfizer (PFE) Announces Strong Data from SUTENT Phase 3 in RCC; DFS Extension Noted

October 10, 2016 8:05 AM EDT

Pfizer Inc. (NYSE: PFE) announced results from the Phase 3 S-TRAC clinical trial (Sunitinib Trial as Adjuvant Treatment of Renal Cancer) investigating SUTENT (sunitinib) as adjuvant therapy. The trial showed SUTENT extended disease-free survival (DFS) by more than one year versus placebo in patients who were at high risk for recurrence after surgical resection of renal cell carcinoma (RCC) (HR 0.761; P=0.030 [95% CI: 0.594-0.975]). These results will be presented today during a Presidential Symposium (Abstract #LBA11_PR) at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology being held in Copenhagen,... More